AxioMx fit-out completed on time and to budget, doubling capacity for in vitro recombinant binder discovery and validation. Successfully completed a number of milestones relating to AxioMx’s intellectual property and technology development and added new products to the catalogue 5. Selectively Continue to actively Entered into a number of Supplement organic pursue partnerships seek out and evaluate new collaborations and growth through and acquisitions new partnerships, continued to explore acquisitions and acquisitions, acquisition and partnerships Our aim is to collaborations and collaboration opportunities supplement the investment Continue to other components opportunities that strengthen of our strategy by support our strategy relationships for future making acquisitions and leverage our deals of and working with competitive partners that add advantage to our competitive advantage in the life science market Our KPIs We measure our performance against a number of KPI targets. Success against these KPIs forms a component of the Executive Directors’ and senior management’s incentives. RabMAb® primary antibodies CER revenue growth Strategic alignment: 1, 2, 4, 5 25% FY 2017 FY 2017 target FY 2016 FY 2015 FY 2014 25% 18%-22% 29.5% 24.2% 17.1% revised in March 2017 to 23%–27% How we performed At a constant exchange rate (CER) growth rate of 25.2%, our RabMAb® revenues, despite increasing the target in March 2017, have again outperformed our high expectations in the year. Non-primary antibody products CER revenue growth Strategic alignment: 2, 5 16% FY 2017 FY 2017 target FY 2016 FY 2015 FY 2014 16% 20%–25% 30.3% 28.2% 34.3%
AxioMx fit-out completed on time and to budget, doubling capacity for in vitro recombinant binder discovery and validation. Successfully completed a number of milestones relating to AxioMx’s intellectual property and technology development and added new products to the catalogue 5. Selectively pursue partnerships and acquisitions Our aim is to supplement the other components of our strategy by making acquisitions of and working with partners that add to our competitive advantage in the life science market Continue to actively seek out and evaluate new partnerships, acquisitions, collaborations and investment opportunities that support our strategy and leverage our competitive advantage Entered into a number of new collaborations and continued to explore acquisition and collaboration opportunities Supplement organic growth through acquisitions and partnerships Continue to strengthen relationships for future deals Our KPIs We measure our performance against a number of KPI targets. Success against these KPIs forms a component of the Executive Directors’ and senior management’s incentives. RabMAb® primary antibodies CER revenue growth Strategic alignment: 1, 2, 4, 5 25% FY 2017 FY 2017 target FY 2016 FY 2015 FY 2014 25% 18%-22% revised in March 2017 to 23%–27% 29.5% 24.2% 17.1% How we performed At a constant exchange rate (CER) growth rate of 25.2%, our RabMAb® revenues, despite increasing the target in March 2017, have again outperformed our high expectations in the year. Non-primary antibody products CER revenue growth Strategic alignment: 2, 5 16% FY 2017 FY 2017 target FY 2016 FY 2015 FY 2014 16% 20%–25% 30.3% 28.2% 34.3%
Abcam-Prelims-Final-11.9.17.docx